Last updated: May 25, 2026
Who supplies trifluoperazine hydrochloride API and finished tablets?
Trifluoperazine hydrochloride is a widely available, off-patent small-molecule antipsychotic. Supply is typically split across (1) API manufacturers and (2) finished-dose tablet producers. Public-facing supplier identification is usually handled through:
- Drug Master Files (DMFs) or API registrations tied to the FDA Drug Listing system
- FDA Orange Book listings for specific NDCs and application holders
- Wholesale distributor catalogs for product-level sourcing
API supplier landscape (how companies generally show up in regulatory and commercial channels)
Most trifluoperazine HCl API supply comes from companies that maintain at least one of the following for the material:
- FDA DMF for drug substance (type not specified in public summaries)
- Regional compliance registrations (EU/UK dossiers and local filings)
- Commercial supply agreements with branded and generic finished-dose manufacturers
Finished-dose suppliers (what to map in the Orange Book)
Finished-dose trifluoperazine hydrochloride tablet supply is best tracked by NDC, labeler, and application holder. Orange Book entries identify:
- Drug product active ingredient (trifluoperazine HCl)
- Dosage form and strength
- Application type (ANDA vs. other pathways)
- Patent and exclusivity status tied to each listed NDA/ANDA
If the goal is procurement or sourcing, mapping by NDC and labeler reduces ambiguity versus listing “manufacturers” without tying them to market authorizations.
What finished-dose manufacturers produce trifluoperazine hydrochloride tablets in the US?
Finished-dose trifluoperazine HCl availability is concentrated among generic manufacturers that support low-cost, legacy antipsychotics. For US sourcing, the operational approach is:
- Pull all Orange Book listings for trifluoperazine hydrochloride tablets
- Capture each application holder (ANDA sponsor) and labeler/NDC
- Then map supply chain contacts for that labeler (direct manufacturer or distributor of record)
Why NDC labeler mapping matters
The “supplier” a buyer contracts with is often the commercial entity tied to the NDC, not the underlying factory. Labeler, MAH/applicant, and manufacturing site can differ.
How do you identify reliable trifluoperazine hydrochloride suppliers using regulatory breadcrumbs?
For procurement-grade supplier qualification, the highest-signal indicators are:
FDA Orange Book (finished-dose)
Use to confirm:
- Which ANDAs/NDCs currently list trifluoperazine HCl tablets
- Which application holders are tied to marketed product
FDA DMF (API)
Use to confirm:
- Which API manufacturers support filings for trifluoperazine hydrochloride drug substance
cGMP inspections and quality history (supplier qualification)
Procurement qualification typically relies on:
- Inspection outcomes (FDA/EMA equivalents)
- Quality agreements and batch release documentation
- Stability and impurity profiles
Which contract manufacturing organizations handle trifluoperazine hydrochloride tablets?
For legacy generics like trifluoperazine, contract manufacturing is common at the formulation and packaging stage even when the API is sourced externally. Contract manufacturing and packaging (including bottle/bank packaging) can be sourced via:
- Generic dosage form specialists
- Sterile vs. non-sterile manufacturing networks (trifluoperazine tablets are non-sterile)
- Labeling and secondary packaging vendors aligned to NDC commitments
The most decision-useful mapping is:
- Product-level manufacturing site for each marketed NDC
- Contract relationships behind the application holder
What API manufacturers supply trifluoperazine hydrochloride to generic drug makers?
API supply for trifluoperazine HCl typically comes from:
- Small-molecule API producers serving multiple branded and generic programs
- Backward integration by some finished-dose manufacturers
- API distributors that aggregate DMF holders and provide commercial inventory
The actionable way to identify specific API suppliers for a procurement deal:
- Identify the API DMF references behind each ANDA
- Confirm the DMF holder (API manufacturer) and cross-check batch release and quality capabilities
Which suppliers are most relevant for wholesale distribution of trifluoperazine hydrochloride?
At the wholesaler level, the practical supplier set is:
- Distributor of record for the specific NDCs in-market
- Manufacturer/labeler that supplies through that distributor
Wholesale availability changes with sourcing and contract cycles, so ongoing NDC and labeler monitoring is the most reliable approach.
What generic entry risks exist that could disrupt trifluoperazine hydrochloride supply?
For an off-patent product, supply risk drivers are usually not “IP barriers” but:
- Drug substance sourcing fragility (single-DMF dependence)
- Manufacturing capacity constraints at one plant
- Regulatory actions affecting API or product batch release
- Discontinuations or temporary shortages tied to economics
The counter is multi-source qualification:
- Qualify both API and finished-dose suppliers
- Require right-to-audit and a change-control agreement for manufacturing transfers
How strong is the patent estate for trifluoperazine hydrochloride, and does it affect supply sourcing?
Trifluoperazine is an older, low-cost generic antipsychotic. In practice, supply sourcing is dominated by commercial and regulatory factors rather than active exclusivity. For buyers, the operational implication is:
- Multiple ANDAs typically exist
- Competitive generic production often reduces single-supplier leverage
What regulatory listings should purchasers verify for each supplier?
For each API or finished-dose supplier, verify:
- US FDA market authorization status for the product (Orange Book/NDC)
- API DMF presence and the DMF holder
- Current labeling and strength compatibility with your intended use
- GMP compliance for the dosage form and manufacturing steps (API, blending, tablet compression, coating, packaging)
Comparison: How supplier selection differs for API vs finished-dose
| Procurement target |
Best evidence |
Key decision variables |
Main risk |
| API trifluoperazine HCl |
FDA DMF holder, impurity profile, COA history |
polymorph/salt specification, impurity limits, batch consistency |
DMF/quality issues disrupt finished-dose supply |
| Finished-dose tablets |
Orange Book NDC list, application holder, labeler |
packaging form, lead time, lot release timing |
NDC discontinuation or site-specific capacity limits |
| Distributor source |
NDC availability, distributor of record |
delivery reliability, price volatility |
sudden stockouts and substitution changes |
Key Takeaways
- Trifluoperazine hydrochloride supply is best sourced via Orange Book mapping (finished-dose NDCs and application holders) and DMF mapping (API DMF holders).
- Contract manufacturing and packaging can shift independently of the API supplier, so buyers should qualify both layers if continuity is critical.
- Supplier robustness is driven more by DMF/batch release continuity and cGMP reliability than by patent-driven exclusivity.
FAQs
-
How do I find the application holder for a specific trifluoperazine hydrochloride tablet NDC?
Use the FDA Orange Book entry tied to that NDC and read the listed applicant/application holder.
-
What’s the difference between an API DMF holder and the commercial API supplier?
The DMF holder is the regulatory source for the drug substance filing; the commercial supplier may be a distributor, a contract packer, or a company with trading rights.
-
Can trifluoperazine hydrochloride tablet manufacturing be outsourced?
Yes. Manufacturing steps such as blending, compression, coating, and packaging are commonly handled by contract facilities even when an ANDA/applicant owns the regulatory application.
-
What supplier qualification documents matter most for legacy generics like trifluoperazine HCl?
Batch COAs, impurity/stability packages, change-control terms, and inspection/quality agreements tied to the manufacturing sites.
-
How can a buyer reduce shortages risk for trifluoperazine hydrochloride?
Qualify multiple sources across both API and finished-dose, and require supply continuity clauses tied to manufacturing site changes and lot release timing.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Master Files (DMF) database information. U.S. Food and Drug Administration.
- FDA NDC Directory. U.S. Food and Drug Administration.
